Episode 62
Biotech Hangout
00:00
The Impact of the 85% Discount to a Humira on Cancer
I think it's personally, I think it's unethical to not provide access to the medicine free of charge after their enrollment in a clinical study. We debated whether the 85% discount to a Humira would actually have a material impact on, on Humira itself for, for Abb. It may actually not make that much of a difference for Abb in particular, but could have an important effect on all the other biosimilar players.
Transcript
Play full episode
